Mucosal adjuvants and anti-infection and anti-immunopathology vaccines based on cholera toxin, cholera toxin B subunit and CpG DNA

被引:142
作者
Holmgren, J
Adamsson, J
Anjuère, F
Clemens, J
Czerkinsky, C
Eriksson, K
Flach, CF
George-Chandy, A
Harandi, AM
Lebens, M
Lehner, T
Lindblad, M
Nygren, E
Raghavan, S
Sanchez, J
Stanford, M
Sun, JB
Svennerholm, AM
Tengvall, S
机构
[1] Univ Gothenburg, Vaccine Res Inst, Dept Med Microbiol & Immunol, SE-40530 Gothenburg, Sweden
[2] Int Vaccine Inst, Seoul, South Korea
[3] INSERM, U364, Fac Med Pasteur, F-06107 Nice, France
[4] Univ London, Guys London Sch Med, London, England
关键词
mucosal adjuvants; anti-infection; anti-immunopathology;
D O I
10.1016/j.imlet.2004.11.009
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Mucosal immunisation may be used both to protect the mucosal surfaces against infections and as a means for immunological treatment of peripheral immunopathological disorders through the induction of systemic antigen-specific tolerance ('oral tolerance'). The development of mucosal vaccines, whether for prevention of infectious diseases or for oral tolerance immunotherapy, requires efficient antigen delivery and adjuvant systems that can help to present the appropriate vaccine or immunotherapy antigens to the mucosal immune system. The most potent (but also toxic) mucosal adjuvants are cholera toxin (CT) and the closely related Escherichia coli heat-labile enterotoxin (LT), and much effort and significant progress have been made recently to generate toxicologically acceptable derivatives of these toxins with retained adjuvant activity. Among these are the non-toxic, recombinantly produced cholera toxin B-subunit (CTB). CTB is a specific protective antigen component of a widely registered oral cholera vaccine as well as a promising vector for either giving rise to mucosal anti-infective immunity or for inducing peripheral anti-inflammatory tolerance to chemically or genetically linked foreign antigens administered mucosally. CT and CTB have also recently been used as combined vectors and adjuvants for markedly promoting ex vivo dendritic cell (DC) vaccination with different antigens and also steering the immune response to the in vivo-reinfused DCs towards either broad Th1 + Th2 + CTL immunity (CT) or Th2 or tolerance (CTB). Another type of mucosal adjuvants is represented by bacterial DNA or synthetic oligodeoxynucleotides containing CpG-motifs, which especially when linked to CTB have been found to effectively stimulate both innate and adaptive mucosal immune responses. The properties and clinical potential of these different classes of adjuvants are being discussed. (c) 2004 Elsevier B.V. All rights reserved.
引用
收藏
页码:181 / 188
页数:8
相关论文
共 41 条
[1]  
Ågren LC, 1999, J IMMUNOL, V162, P2432
[2]  
[Anonymous], 2001, Wkly Epidemiol Rec, V76, P117
[3]  
[Anonymous], NEW GENERATION VACCI
[4]   A plant-based cholera toxin B subunit - insulin fusion protein protects against the development of autoimmune diabetes [J].
Arakawa, T ;
Yu, J ;
Chong, DKX ;
Hough, J ;
Engen, PC ;
Langridge, WHR .
NATURE BIOTECHNOLOGY, 1998, 16 (10) :934-938
[5]   A cholera toxoid-insulin conjugate as an oral vaccine against spontaneous autoimmune diabetes [J].
Bergerot, I ;
Ploix, C ;
Petersen, J ;
Moulin, V ;
Rask, C ;
Fabien, N ;
Lindblad, M ;
Mayer, A ;
Czerkinsky, C ;
Holmgren, J ;
Thivolet, C .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1997, 94 (09) :4610-4614
[6]   Oral administration of recombinant cholera toxin subunit B inhibits IL-12-mediated murine experimental (trinitrobenzene sulfonic acid) colitis [J].
Boirivant, M ;
Fuss, IJ ;
Ferroni, L ;
De Pascale, M ;
Strober, W .
JOURNAL OF IMMUNOLOGY, 2001, 166 (05) :3522-3532
[7]   IDENTIFICATION OF RANTES, MIP-1-ALPHA, AND MIP-1-BETA AS THE MAJOR HIV-SUPPRESSIVE FACTORS PRODUCED BY CD8(+) T-CELLS [J].
COCCHI, F ;
DEVICO, AL ;
GARZINODEMO, A ;
ARYA, SK ;
GALLO, RC ;
LUSSO, P .
SCIENCE, 1995, 270 (5243) :1811-1815
[8]   Mucosal immunity and tolerance: relevance to vaccine development [J].
Czerkinsky, C ;
Anjuere, F ;
McGhee, JR ;
George-Chandy, A ;
Holmgren, J ;
Kieny, MP ;
Fujiyashi, K ;
Mestecky, JF ;
Pierrefite-Carle, V ;
Rask, C ;
Sun, JB .
IMMUNOLOGICAL REVIEWS, 1999, 170 :197-222
[9]  
CZERKINSKY C, 1995, IMMUNOLOGIST, V3, P97
[10]   Coupling of antigen to cholera toxin for dendritic cell vaccination promotes the induction of MHC class I-restricted cytotoxic T cells and the rejection of a cognate antigen-expressing model tumor [J].
Eriksson, K ;
Sun, JB ;
Nordström, I ;
Fredriksson, M ;
Lindblad, M ;
Li, BL ;
Holmgren, J .
EUROPEAN JOURNAL OF IMMUNOLOGY, 2004, 34 (05) :1272-1281